April 2, 2026 POLAR is a randomized, double-blind, placebo-controlled study that enrolled 43 patients with PMM2-CDG across 15 sites globally with topline data expected in the fourth quarter of 2026 Primary endpoint evaluates change in ataxia at 24 weeks, as measured by the International Cooperative Ataxia Rating Scale (ICARS) SAN CARLOS, Calif., April 2, 2026…
View detailsMay 11, 2026 PDF Version Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors Strengthened balance sheet with oversubscribed $299 million equity financing; cash position expected to fund operations into 2H 2028 BOSTON, May 11, 2026 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ:…
View detailsMay 5, 2026 PDF Version BOSTON, May 05, 2026 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the closing of its previously announced underwritten public offering. In the offering, Aura sold (i) 46,099,650 shares of common stock, which includes 6,508,650 shares…
View detailsMay 4, 2026 PDF Version BOSTON, May 04, 2026 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 39,591,000 shares of its common stock and (ii) in lieu of common stock to…
View detailsMay 4, 2026 PDF Version BOSTON, May 04, 2026 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants…
View detailsMay 4, 2026 PDF Version Natalie Holles, seasoned industry executive with significant rare disease operational and commercialization experience, appointed Chief Executive Officer and President and member of the Board of Directors Acceleration in patient screening driving Phase 3 CoMpass trial enrollment to near completion BOSTON, May 04, 2026 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology…
View detailsAura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights March 30, 2026 PDF Version Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 12-month Stability Completed with New Formulation with Potential Across…
View detailsFebruary 25, 2026PDF Version BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: TD Cowen 46th Annual Health Care Conference…
View details